New Horizons in the Management of Sickle Cell Disease (SCD): Leveraging Treatment Breakthroughs to Make Informed Decisions in Managed Care

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Sickle Cell Disease

These are archives of live webinars held between December 4 to December 17, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These activities are valid from January 1, 2020 to January 1, 2023

This series is supported by educational grants from
Global Blood Therapeutics and Novartis

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Sickle cell disease (SCD) is a chronic, life-long, debilitating disease with many forms that can range in clinical severity from asymptomatic to life-threatening. In the US, SCD affects an estimated 90,000 to 100,000 Americans. This disease can lead to the obstruction of blood vessels, reduced blood flow to vital organs, and a weakened immune system. Fortunately for patients, novel therapies have been approved that have shown tremendous benefit in SCD.

What Managed Care Needs to Know about New and Emerging Therapies in Management of Sickle Cell Disease

1. Analyze the economic burden of sickle cell disease (SCD) and the impact of suboptimal management on outcomes
2. Review the latest clinical data on newer therapies in SCD
3. Assess approaches currently utilized by third party payers to manage costs associated with the care of patients with SCD
4. Discuss the managed care considerations of novel therapies by exploring where these agents may fit into current SCD management paradigm
5. Identify co-productive payer-provider strategies to ensure appropriate and timely access to new therapies for vaso-occlusive pain events in SCD
6. Transform therapeutic advances and resource utilization data in SCD into informed health plan decisions and formulary discussionsnalyze the economic burden of Alzheimer’s disease (AD) and the impact of suboptimal management on outcomes

A Deeper Look into New Therapies in the Management of Sickle Cell Disease: How the Latest Advances May Impact Decision-Making

1. Discuss the pathophysiology, physical manifestations, economic burden, clinical course, and impact on patient quality of life of sickle cell disease (SCD)
2. Examine the mechanisms underlying new and emerging treatments for patients with SCD that work upstream of sickle hemoglobin (HbS) polymerization and may be disease-modifying
3. Evaluate the latest clinical evidence regarding new and emerging disease-modifying options for patients with SCD and the implications for patients
4. Analyze the safety and efficacy of new therapies that manage acute vaso-occlusive pain events in SCD
5. Examine the latest understanding regarding SCD phenotypes and implications for treatment selection and sequencing
6. Identify patients with vaso-occlusive pain events in SCD for whom a newer therapy is an appropriate choice for the next step in the management of their disease

Improving Patient Adherence and Quality of Life in Sickle Cell Disease: Strategies for Managing Adverse Events Associated with New and Emerging Therapies

1. Examine challenges to patient adherence, administration and quality of life in the management of sickle cell disease (SCD)
2. Review strategies to implement new and emerging therapies into the treatment paradigm, especially as it relates to patient adherence and quality of life
3. Evaluate strategies to monitor and manage adverse events associated with novel therapies in SCD in order to improve patient adherence and quality of life
4. Analyze the safety and efficacy of new therapies that manage acute vaso-occlusive pain events in SCD
5. Implement individualized treatment plans based on evidence-based monitoring strategies for patients acute vaso-occlusive crisis in SCD